News on Peripheral T-cell lymphoma

New characteristics and markers regarding prognosis within subtypes can be found in Table 1.

A retrospective study analyzed 224 patients from 1992–2019 and compared OS between conventional chemotherapy and new targeted treatment. New targeted treatment and improved genetic, epigenetic, and transcriptional characterization of distinct subtypes showed significantly longer OS over the past three decades [4].

One of the most promising emerging drugs against peripheral T cell lymphomas is brentuximab vedotin (BV). BV is an immune conjugate combining a CD30-antibody and the toxic mono-methyl-auristatin E (MME). In 2012, BV was approved by the US Food and Drug Administration (FDA) for the characteristically CD30-positive PTCL subtype, anaplastic large T cell lymphoma (ALCL).

In the ECHELON-2 study from Horwitz et al. in 2019, the global, double-blind, randomized, phase 3 trial showed frontline treatment with BV+CHP was superior to CHOP for 452 patients with CD30-positive peripheral T‑cell lymphomas [5]. The impressive results of CR responses of 68% for BV+CHP and 56% for CHOP and a significantly improved progression-free survival (PFS) of 48.8 months for BV+CHP compared to 20.8 months for CHOP prompted FDA-approval of BV+CHP as first-line treatment for CD30+ PTCL (Fig. 1). European Medicines Agency (EMA) guidelines are more restrictive and BV+CHP is indicated only in ALCL (characteristically CD30 positive) as first-line treatment.

In the setting of relapsed or refractory PTCL, histone deacytelase inhibitors, such as belinostat and romidepsin showed responses of 13–17 months and achieved FDA approval in 2011 (but not EMA approval). These promising results lead to several combinational studies with HDAC inhibitors as the Ro-CHOP trial. The well-designed Ro-CHOP trial conducted by Bachy et al. from Lyon randomized 421 patients into a Ro-CHOP vs. a CHOP group. Unfortunately, the final results were disappointing and showed no significant improvement in OS and PFS for the Ro-CHOP group, but higher toxicities compared to the standard treatment of CHOP ([6]; Fig. 2a) These disillusioning results were repeated in an additional study, which had to be stopped due to insufficient responses and PFS (48% of the patients achieved PFS of 18 months) [7].

However, the response of the PTCL subgroup of AITL (angioimmunoblastic T‑cell lymphoma) to Ro-CHOP showed encouraging results. This observation aligns with previously found insights into the epigenetic deregulation in AITL due to mutations in the TET2 or DNMT3A genes, which are responsible for epigenetic modulation in T cells. These subgrouping results give promising insights into the effectiveness of Ro-CHOP in AITL, although further studies are still needed ([1, 6]; Fig. 2b).

The high mutational burden in the epigenetic modulator genes TET2 and DNMTR3 in AITL also provided the basis for further clinical studies testing the hypomethylating agent azacytidine. O’Connor et al. tested a combination of azacytidine with romidepsin and showed an ORR in a phase 1 trial of 73% and complete remissions in 55% in the setting of relapsed/refractory (r/r) AITL. In the next step, a randomized study compares orally applied azacytidine against romidepsin, gemcitabine or bendamustine monotherapy in r/r AITL (NCT03593018; 86 participants, recruiting closed).

Studies evaluating the role of autologous stem cell transplantation (SCT) are unfortunately discordant. Randomized clinical trials are still missing and retrospective evidence is “for” and “against”. There are a few prospective clinical trials, but because of diverse subtype inclusion comparisons are difficult.

Recently, Brink et al. analyzed 1427 patients < 65 years divided in two cohorts retrospectively and consolidation with ASCT in first-line setting significantly increased 5‑year OS (78% vs 45% without ASCT) in ALK-negative ALCL, AITL, and PTCL NOS [8].

To assess the clear role of autoSCT in PTCL a randomized clinical trial has been launched recently (TRANSCRIPT – NCT05444712, planned patients: 204, ECOG 0–2, including PTCL-NOS, TFH-TCL, ALCL-ALK neg).

Peripheral T cell lymphoma, especially the angioimmunoblastic T‑cell lymphoma subtype, show histologically a rich environment of infiltrating immune cells. Malignant T cells cleverly escape these checkpoints. Unfortunately, conducted studies with PD‑1 inhibitors showed even contrary results in PTCL and disease progression was experienced.

Another approach is to block the CD47 glycoprotein, the “do-not-eat me” marker for macrophages, on PTCL cells, which is found to be overexpressed in some PTCL cases [9].

Furthermore, blocking the killer-cell immunoglobulin-like receptor KIR3DL2, which is found to be overexpressed in PTCL, showed efficacy in cutaneous T cell lymphoma. KIR3DL2 is also found on some nodal PTCL cases. The TELLOMAK phase II study is therefore testing the KIR3DL2-antibody IPH4102 in PTCL (NCT03902184) [10].

Targeting the SYK/JAK-signaling pathway, as cerdalutinib inhibits SYK, JAK1, JAK3 and Tyk2, and showed responses especially in TFH/AITL and ALCL subtypes. The SYK-signaling pathway is important for the malign transformation in T cells and is overactivated in 90% of ALCL, AITL and PTCL, NOS [11].

The emerging field of CAR‑T and NK (natural killer cells) treatment is also entering the field of T cell lymphoma. So far CAR-T/NK studies are still in a preclinical phase, but larger clinical studies are recruiting or underway. One of the major challenges in CAR‑T cells engineered for T cell lymphoma are fratricide effects—CAR‑T cells recognizing T‑cell antigens and targeting other CAR‑T cells. However, genetic modification of CAR-Ts might resolve this issue [12]. Another problem occurs regarding T cell aplasia: As the human immune system can compensate for a complete B‑cell deprivation, pan T‑cell aplasia leads to severe immunodeficiency.

An alternative approach targeting only malignant T cells is to focus on the exclusive expression of the T‑cell receptor β‑chain 1 or 2. Targeting only the malignant clone expressing one of the two T‑cell receptor β‑chains provides a substantial fraction of physiological T‑cells with the contrary T‑cell receptor β‑chain in the mouse model [13].

Other CAR-engineered T or NK cells target CD3, CD4, CD5, CD7, CD30 or CCR4 [14].

CAR-NK cells have the advantage of circumventing the HLA-matching restriction. The abundant source makes it potentially available to be an off-the-shelf product that could be readily available for immediate clinical use [15].

Functional in vitro drug screening of patient-derived real-time tumor biopsies is another approach to test the plethora of clinically available anticancer drugs for patients with rare diseases like T cell lymphoma directly. In the prospective clinical EXALT trial, functional drug screening was applied to test 136 small molecule drugs on primary patient tumor cells. The most effective in vitro hits were integrated in clinical drug selection for each individual patient. Especially the heterogeneous subgroup of patients with T cell lymphomas demonstrated a benefit in median PFS compared to B‑cell malignancies [16].

Precise genetic and epigenetic patient stratification in the heterogenous diagnosis of peripheral T cell lymphoma will help guide treatment selection in the future.